Recent Finacing
Recent Raise
Drug Response Dx develops biomarker-based diagnostic test kits to predict TNF‑alpha inhibitor response in rheumatoid arthritis, using Max‑Planck‑Innovation–licensed technology, ELISA antibody verification, and producing high-quality biomarkers at scale.
Focus Areas
Recent Investors
Funding round
Investors